NASDAQ:EVFM - Evofem Biosciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.33 -0.27 (-4.82 %)
(As of 05/20/2019 04:00 PM ET)
Previous Close$5.60
Today's Range$5.10 - $5.42
52-Week Range$1.79 - $7.24
Volume68,101 shs
Average Volume139,164 shs
Market Capitalization$188.52 million
P/E RatioN/A
Dividend YieldN/A
Beta1.58
Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of chlamydia and gonorrhea in women. The company is also developing multi-purpose vaginal pH regulator gel product candidate for the reduction of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Receive EVFM News and Ratings via Email

Sign-up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EVFM
CUSIPN/A
Phone858-550-1900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.82) per share

Profitability

Net Income$-125,710,000.00

Miscellaneous

Employees30
Market Cap$188.52 million
Next Earnings Date8/1/2019 (Estimated)
OptionableNot Optionable

Evofem Biosciences (NASDAQ:EVFM) Frequently Asked Questions

What is Evofem Biosciences' stock symbol?

Evofem Biosciences trades on the NASDAQ under the ticker symbol "EVFM."

How were Evofem Biosciences' earnings last quarter?

Evofem Biosciences Inc (NASDAQ:EVFM) announced its earnings results on Tuesday, May, 7th. The biotechnology company reported ($0.50) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.45) by $0.05. View Evofem Biosciences' Earnings History.

When is Evofem Biosciences' next earnings date?

Evofem Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Evofem Biosciences.

What price target have analysts set for EVFM?

5 equities research analysts have issued 12 month price targets for Evofem Biosciences' shares. Their forecasts range from $8.00 to $15.00. On average, they anticipate Evofem Biosciences' stock price to reach $11.10 in the next twelve months. This suggests a possible upside of 108.3% from the stock's current price. View Analyst Price Targets for Evofem Biosciences.

What is the consensus analysts' recommendation for Evofem Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evofem Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evofem Biosciences.

What are Wall Street analysts saying about Evofem Biosciences stock?

Here are some recent quotes from research analysts about Evofem Biosciences stock:
  • 1. According to Zacks Investment Research, "Evofem Biosciences Inc. develops and anticipates commercializing products which support and promote women as the primary healthcare consumer. The company is identifying and developing new and novel products which specifically address unmet needs in the areas of sexual and reproductive health, the prevention of acquisition of sexually transmitted infections and products which address or promote general health and wellbeing. Evofem Biosciences Inc., formerly known as Neothetics Inc., is based in SAN DIEGO CA. " (5/13/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate the Overweight rating and $9 PT for EVFM stock. We continue to believe Amphora, if successfully developed, could become an important new contraceptive modality for women electing not to use hormonal or device-related methods. The company is making progress on a long-term financing strategy to fund pre-commercial and, if approved, launch activities of Amphora that may involve potential sources of non-dilutive capital, which we believe may benefit shareholders." (3/4/2019)

Has Evofem Biosciences been receiving favorable news coverage?

Media coverage about EVFM stock has trended somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Evofem Biosciences earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days.

Who are some of Evofem Biosciences' key competitors?

What other stocks do shareholders of Evofem Biosciences own?

Who are Evofem Biosciences' key executives?

Evofem Biosciences' management team includes the folowing people:
  • Ms. Saundra Pelletier, CEO & Director
  • Mr. Justin J. File, Chief Financial Officer (Age 49)
  • Dr. Kelly Culwell, Chief Medical Officer
  • Mr. Jason Abrams, Accounting Mang.
  • Mr. Alexander A. Fitzpatrick, Exec. VP, Gen. Counsel & Sec. (Age 52)

Who are Evofem Biosciences' major shareholders?

Evofem Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Northern Trust Corp (0.10%) and BlueCrest Capital Management Ltd (0.07%). Company insiders that own Evofem Biosciences stock include Alexander A Fitzpatrick, Kelly Culwell, Ltd Invesco, Russell Barrans, Saundra L Pelletier and Thomas G Lynch. View Institutional Ownership Trends for Evofem Biosciences.

Which institutional investors are buying Evofem Biosciences stock?

EVFM stock was purchased by a variety of institutional investors in the last quarter, including Northern Trust Corp and BlueCrest Capital Management Ltd. Company insiders that have bought Evofem Biosciences stock in the last two years include Alexander A Fitzpatrick, Kelly Culwell, Ltd Invesco, Russell Barrans, Saundra L Pelletier and Thomas G Lynch. View Insider Buying and Selling for Evofem Biosciences.

How do I buy shares of Evofem Biosciences?

Shares of EVFM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Evofem Biosciences' stock price today?

One share of EVFM stock can currently be purchased for approximately $5.33.

How big of a company is Evofem Biosciences?

Evofem Biosciences has a market capitalization of $188.52 million. The biotechnology company earns $-125,710,000.00 in net income (profit) each year or ($5.74) on an earnings per share basis. Evofem Biosciences employs 30 workers across the globe.

What is Evofem Biosciences' official website?

The official website for Evofem Biosciences is http://www.evofem.com.

How can I contact Evofem Biosciences?

Evofem Biosciences' mailing address is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-550-1900 or via email at [email protected]


MarketBeat Community Rating for Evofem Biosciences (NASDAQ EVFM)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  170 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  304
MarketBeat's community ratings are surveys of what our community members think about Evofem Biosciences and other stocks. Vote "Outperform" if you believe EVFM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVFM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/20/2019 by MarketBeat.com Staff

Featured Article: Roth IRA

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel